The Macerich Company (MAC)
Stay Ahead of the Game With Macerich (MAC) Q4 Earnings: Wall Street's Insights on Key Metrics
Beyond analysts' top -and-bottom-line estimates for Macerich (MAC), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
Macerich Stock Up 20.7% in Six Months: Will the Trend Last?
MAC is set to benefit from a premium shopping center portfolio, efforts to support omnichannel retailing and balance-sheet strengthening amid higher tenant bankruptcies.
Is Macerich Now A Buy?
Macerich has rallied heavily over the last year as market enthusiasm builds over its Path Forward Plan. The REIT is currently trading for 13.5x times its annualized third-quarter FFO and offers a modest 3.31% dividend yield. The November equity offering should be accretive, but revenue is set to dip in future quarters on asset sales and givebacks.
Macerich Stock Up 29.6% in 3 Months: Will the Momentum Continue?
MAC's premium shopping centers portfolio is likely to gain from healthy retail demand, aiding higher leasing activity and focus on omnichannel retailing.
Why Is Macerich (MAC) Up 13.3% Since Last Earnings Report?
Macerich (MAC) reported earnings 30 days ago. What's next for the stock?
Why developers are turning to shopping malls to fix the housing crisis
More people are living at American malls as real estate developers knock down department stores and construct apartment buildings in their place. At least 192 U.S. malls planned to add housing to their footprint as of January 2022, and at least 33 had constructed apartments since the pandemic began.
Macerich's Q3 FFO Lags Estimates, Revenues Increase Y/Y
MAC's Q3 performance reflects a year-over-year increase in interest expenses. However, same-center NOI, including lease termination income, rises.
The Macerich Company (MAC) Q3 2024 Earnings Conference Call Transcript
The Macerich Company (NYSE:MAC ) Q3 2024 Earnings Conference Call November 5, 2024 11:00 PM ET Company Participants Samantha Greening - Director of IR Jack Hsieh - President, CEO and Director Doug Healey - SEVP of Leasing Scott Kingsmore - SEVP, CFO and Treasurer Conference Call Participants Jeffrey Spector - Bank of America Securities Floris van Dijkum - Compass Point Craig Mailman - Citi. Samir Khanal - Evercore Alexander Goldfarb - Piper Sandler Michael Mueller - JPMorgan Linda Tsai - Jefferies Caitlin Burrows - Goldman Sachs Haendel St Juste - Mizuho Operator Ladies and gentlemen, thank you for standing by.
Macerich (MAC) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Macerich (MAC) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Macerich (MAC) Q3 FFO Lag Estimates
Macerich (MAC) came out with quarterly funds from operations (FFO) of $0.38 per share, missing the Zacks Consensus Estimate of $0.40 per share. This compares to FFO of $0.44 per share a year ago.
Macerich (MAC) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Macerich (MAC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions
The pricing announcement from the Center for Medicare Services became effective on October 1, 2024, and allows BioStem to begin marketing initiatives with Venture Medical POMPANO BEACH, Fla., October 29, 2024 – PRISM MediaWire – BioStem Technologies Inc.
